Please ensure Javascript is enabled for purposes of website accessibility

2 Biotech Stocks with Jaw-Dropping Growth Potential

By George Budwell - Sep 13, 2020 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sorrento Therapeutics and Trillium Therapeutics could both be poised for another explosive move higher.

Biotech stocks have proven time and again to be outstanding growth vehicles for risk-tolerant investors. Underscoring this point, companies like Axsome Therapeutics, Immunomedics, and Novavax have each generated enormous returns on capital for investors within an exceedingly short period of time. 

Which biotech stocks might be the next big gainers? While it's frankly impossible to predict the next Axsome, Immunomedics, or Novavax with any degree of certainty, the small-cap biotechs Sorrento Therapeutics (SRNE 6.05%) and Trillium Therapeutics (TRIL) appear to have a real shot at following in their footsteps from a growth standpoint. Here's a brief overview of the potential risks and rewards associated with these two small-cap biotech stocks. 

A woman holding a fanned out stack of hundred dollar bills while standing in front of a light blue background.

Image source: Getty Images.

Sorrento: A battleground coronavirus stock

Sorrento essentially sports three core product development platforms: COVID-19 drug, vaccine, and diagnostic products; immuno-oncology, and pain management. Investors, though, have clearly keyed in on the company's suite of experimental COVID-19 products this year.

The underlying reason is that Sorrento is developing one of the most comprehensive COVID-19 platforms in the industry. The company's COVID-19 pipeline currently consists of an early stage vaccine known as T-VIVA-19, a powerful neutralizing antibody dubbed STI-1499 (aka COVI-Guard), a rescue intervention therapy, abivertinib, indicated for patients suffering from acute respiratory distress, along with antibody and saliva diagnostics -- COVI-Track and COVI-Trace, respectively.

Taken together, these COVID-19 product candidates may be worth billions in future sales for the biotech. Wall Street, in fact, has Sorrento's high-end revenue estimate for 2021 coming in at a lofty $3 billion, thanks mainly to its COVID-19 franchise. That's quite a potential haul for a company with a market cap of $1.62 billion at the time of writing. 

Sorrento's COVID-19 aspirations have drawn a fair amount of criticism from short-sellers, however. The short-thesis is that the company won't be able to beat out the wave of competitors for any of its COVID-19 product candidates. COVI-Guard, for instance, is unlikely to beat similar therapies to market from either Eli Lilly or Regeneron. The vaccine space, on the other hand, could be oversaturated by the time T-VIVA-19 even makes it into a pivotal stage trial.  

The bottom line is that Sorrento is a high-risk, high-reward biotech stock. If the company can break into the COVID-19 space with one or more products in a timely manner, its shares should skyrocket. If not, the biotech may be in for a sharp pullback. Invest accordingly. 

Trillium: A cancer stock with lots of room to run

Trillium's shares are presently up by a staggering 1,260% so far this year. The biotech's stock has taken flight in 2020 for three key reasons:

  1. AbbVie and Gilead Sciences have both recently invested huge sums of money in CD47-based cancer therapies -- a novel immune checkpoint pathway. In simplest terms, CD47-based therapies target an innate checkpoint pathway, also known as the "don't eat me signal", employed by some cancer cells to evade immune detection. Trillium's lead clinical candidates, TTI-621 and TTI-622, are both CD47-targeting antibodies. Hence, the sudden interest from Wall Street and retail investors alike. 
  2. Last week, Trillium reported that the ongoing dose-escalation studies for TTI-621 and TTI-622 are going well. The company thus plans on exploring the safety, and preliminary efficacy signals, of these cancer-fighting therapies at higher doses.
  3. Big pharma titan Pfizer invested $25 million in Trillium's common stock last week. This equity stake is fairly small in absolute terms, but it might be a prelude to a larger investment later down the road. 

What's the risk? The CD47 arena has quickly become the next big thing in immuno-oncology. But that doesn't mean that Trillium will be a major player in the space once everything is said and done. Gilead, through its $4.7 billion buyout of Forty Seven earlier this year, is much further along in the clinical trials process.

It is also interesting to note that AbbVie passed over Trillium in its quest for a CD47 asset. What that means is unclear exactly, but AbbVie has been fairly successful at picking winners when it comes to early stage clinical candidates -- with the one glaring exception of its rather costly failure in immunotherapy, Rova-T.

What's the potential reward? Even after Trillium's explosive move higher this year, the company's market cap remains in small-cap territory at $1.2 billion. That's not surprising, given that its lead clinical assets are only in dose-escalation studies at this point.

But it would be shocking if the biotech's value didn't rise into large cap territory (greater than $10 billion) if and when these high-value compounds enter late-stage trials. Stated simply, Trillium's stock might be capable of another 1,000% gain over the next two to three years.    

George Budwell owns shares of AbbVie and Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Immunomedics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$2.63 (6.05%) $0.15
Trillium Therapeutics Inc. Stock Quote
Trillium Therapeutics Inc.
TRIL
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$308.08 (2.63%) $7.89
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.11 (3.77%) $1.82
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.96 (0.82%) $0.51
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$628.71 (0.77%) $4.81
Immunomedics, Inc. Stock Quote
Immunomedics, Inc.
IMMU
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$142.60 (0.37%) $0.52
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$41.47 (2.80%) $1.13
Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
AXSM
$46.27 (2.10%) $0.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.